Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial

Eur J Cancer. 2018 Sep:101:105-113. doi: 10.1016/j.ejca.2018.06.015. Epub 2018 Jul 20.

Abstract

Background: The major prognostic relevance of primary tumour location (LPT) in advanced colorectal cancer was shown in large retrospective studies, but quantitative estimates are highly heterogeneous, and there is still limited information about its impact within the framework of biomarker-guided treatment strategies. Therefore, we analysed LPT in relation to other clinical and molecular parameters, based on mature survival data from the recent randomised AIO KRK0207 trial.

Methods: Patients uniformly received first-line induction treatment with a combination of bevacizumab, oxaliplatin and fluoropyrimidine. LPT was retrospectively determined using surgical reports, pathology reports and endoscopy reports. The prognostic analyses were performed using Kaplan-Meier estimations and log-rank tests, while hazard ratios (HRs) and multivariable results were derived from Cox models.

Results: Among 754 patients with unequivocal information on LPT, patients with left-sided tumours showed a median overall survival of 24.8 months compared with the right-sided cohort with 18.4 months (HR: 1.54, 95% confidence interval: 1.30-1.81, P < 0.0001). In a multivariable model, LPT proved to be the strongest prognosticator (HR 1.60), with performance status, number of metastatic sites, baseline carcinoembryonic antigen (CEA) and platelets independently retaining prognostic significance. In the subgroup of patients with known RAS/BRAF status (n = 567, 75%), a BRAF mutation showed the greatest unfavourable impact (HR 3.16). Although BRAF is strongly correlated to LPT, the latter remained a significant prognosticator in the BRAF wild-type subgroup. In contrast, no major impact of LPT was seen on tumours carrying RAS mutations.

Conclusions: Within the framework of a uniform treatment strategy according to the current standards, LPT proved to have an important, although not solely dominating, relevance for survival prognosis. Its impact seems to be low in tumours with a RAS mutation.

Registration: ClinicalTrials.govNCT00973609.

Keywords: BRAF mutation; Bevacizumab; Colorectal cancer; First-line therapy; Overall survival; Primary tumour location; Prognostic factors; RAS mutation.

Publication types

  • Clinical Trial, Phase III
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bevacizumab / administration & dosage
  • Colon / drug effects*
  • Colon / metabolism
  • Colon / pathology
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / genetics
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Maintenance Chemotherapy
  • Male
  • Middle Aged
  • Mutation
  • Oxaliplatin / administration & dosage
  • Prognosis
  • Proto-Oncogene Proteins B-raf / genetics
  • Rectum / drug effects*
  • Rectum / metabolism
  • Rectum / pathology
  • Retrospective Studies
  • Young Adult
  • ras Proteins / genetics

Substances

  • Oxaliplatin
  • Bevacizumab
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • ras Proteins

Associated data

  • ClinicalTrials.gov/NCT00973609